Accriva Diagnostics, Inc. recalls directCHECK ACT-LR whole blood quality control
- Recalling company
- Accriva Diagnostics, Inc.
- Product
- directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2
- Reason
- Assayed Whole blood control contains labeling with incorrect performance range.
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Apr 30, 2026
- Reported
- Jun 24, 2026
- Distribution
- Worldwide - US Nationwide distribution including in the states of AL, AR, AZ, CA, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, MT, NC, NJ, NM, NY, OH, OK, PA, SC, TN, TX, VA, VT, WA, WI, WV and the countries of Canada, Hong Kong, Spain.
- Status
- Ongoing
- Quantity
- 6060
- Lot / codes
- Lot #: A6DLA001 Unique Device Identifier: 10711234170373
- Company location
- San Diego, CA
- Recall type
- Voluntary: Firm initiated
- Recall number
- Z-2460-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number Z-2460-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.